Dare Bioscience receives U.S. patent covering topical lopinavir/ritonavir for HPV-related cervical conditions

Dare Bioscience received U.S. Patent No. 12,678,439 covering topical lopinavir/ritonavir formulations for HPV-related cervical pathologies, strengthening its DARE-HPV program, a self-administered vaginal insert it describes as a potential first FDA-approved pharmacologic treatment for HPV infection. Exclusive U.S. license protection is expected into at least 2039.

Detected & updated continuously · Source: Nebula